Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2025 Apr 24;5(4):e0004538. doi: 10.1371/journal.pgph.0004538

PrEP in the key population community: A qualitative study of perspectives on pre-exposure prophylaxis by gay, bisexual and other men who have sex with men and female sex workers in Kigali, Rwanda

Jonathan Ross 1,*, Josephine Gasana 2, Natalia Zotova 1, Giovanni Ndabakuranye 2, Fabiola Mabano 2, Charles Ingabire 2, Adebola Adedimeji 3,4, Gad Murenzi 2, Viraj V Patel 1
Editor: Marie A Brault5
PMCID: PMC12021139  PMID: 40273073

Abstract

Gay, bisexual and other men who have sex with men (GBMSM) and cisgender female sex workers (FSW) are increasingly and disproportionately impacted by HIV in sub-Saharan Africa, yet current PrEP care models in this region are not optimized for these communities. Limited data exist describing experiences and preferences of GBMSM and FSW with respect to accessing and using PrEP. We conducted qualitative, semi-structured interviews with GBMSM and FSW recruited from three health centers and seven community organizations in Kigali, Rwanda. Data were analyzed using a mixed deductive and inductive approach to describe key themes related to initiating and adhering to PrEP. Participants included 18 GBMSM and 14 FSW; 12 were using PrEP at the time of interview, 9 had previously used PrEP, and 11 had never used it. Participants highlighted the central role of their social networks as key sources of information about and support for PrEP use, and described a strong motivation to use PrEP as a way to protect both themselves and their communities from HIV. While stigma and discrimination were pervasive, these were experienced differently by GBMSM and FSW. Participants suggested community access points that allowed more discreet and less frequent contact with health care workers as important and desired strategies to improve engagement. These findings suggest that leveraging community resources for disseminating information about HIV prevention and delivering PrEP could contribute to successful implementation of PrEP for GBMSM and FSW in Rwanda and other settings in SSA.

Background

Nearly three-quarters of the 34 million people living with HIV reside in sub-Saharan Africa (SSA) [1]. Gay, bisexual and other men who have sex with men (GBMSM) and cisgender female sex workers (FSWs) are among the key populations (KPs) who are at the highest risk of HIV, and are increasingly and disproportionately represented among new HIV infections in SSA and globally [2–4].

Pre-exposure prophylaxis (PrEP) is highly effective in preventing HIV [5–8]. In its 2016 guidelines, the World Health Organization recommended PrEP for all individuals at substantial risk of HIV [9]. Currently, more than half of global PrEP users reside in SSA, where over 1 million individuals received a prescription in 2022 [10]. While most national PrEP programs in SSA prioritize KPs [11], current care models are not optimized for them. For example, in Rwanda, PrEP is available in primary health centers, settings where key populations may face discrimination and stigma [12]. Thus, despite high willingness to use PrEP among GBMSM and FSW [13–17], engagement remains low [18–20]. Evidence to date suggests that individual (e.g., health literacy, physical and sexual violence, stigma), institutional (e.g., discrimination in health settings), and structural factors (e.g., poverty, anti-homosexuality legislation) impact the opportunity cost around accessing health services and contribute to limited PrEP use [21–25].

Rwanda is a landlocked country situated in central Africa with a total population of 13 million; the largest and capital city is Kigali, with an approximate population of 1.8 million [26]. A majority of the estimated 14,000 FSW (2021 population size estimate [27]) and 18,000 GBMSM (2023 population size estimate [28]) in Rwanda live in Kigali, where the HIV prevalence is higher (4.3%) than the national prevalence of 3% [29]. HIV prevalence among KPs in Rwanda is markedly higher, estimated at 46% among FSW in Kigali and 7% among GBMSM [30]. Rwanda decriminalized same-sex relationships as well as sex work in 2018, but does not have legal recognition for transgender persons. Nonetheless, there are no anti-discrimination laws specifically protecting lesbian, gay, bisexual transgender and intersex (LGBTI) persons, and same-sex marriages are not recognized. Overall, Rwandan society remains socially conservative, with relatively low support for LGBTQ rights [31].

In February 2019, the government of Rwanda began implementing oral PrEP for KPs as part a comprehensive HIV prevention package [32]. Initial efforts in Rwanda focused on FSW, GBMSM and serodifferent couples; more recently efforts have been made to expand PrEP to adolescent girls and young women, index sex partners and individuals in the general population with considerable risk of HIV acquisition. Nonetheless, few data exist on experiences and practices of Rwandan FSW and GBMSM with respect to accessing and using PrEP. To explore these relationships, we conducted a qualitative study to understand barriers to, facilitators of and preferences for PrEP use among Rwandan GBMSM and FSW.

Methods

Ethics statement

The Rwanda National Ethics Committee (RNEC approval number 700/RNEC/2021) and the Institutional Review Board of the Albert Einstein College of Medicine (2020–12619) approved the study, which was conducted according to the principles expressed in the Declaration of Helsinki and is reported in accordance with Consolidated Criteria for Reporting Qualitative Research (COREQ) guidelines [33]. Written informed consent forms were also obtained from all participants prior to study enrollment. The informed consent forms were kept in a locked office, transcripts were de-identified, and audio-recordings were destroyed after transcription.

Study setting and population

PrEP implementation in Rwanda has been rolled out in stages, with a focus on key populations as groups at higher risk of acquiring HIV, particularly FSW and GBMSM. By the end of June 2023, the number of FSW and GBMSM initiating PrEP medication had gradually increased from 10,078 in July 2022–10,789 in June 2023 [34]. While national data on retention are currently unavailable, early studies have demonstrated high PrEP persistence among both GBMSM and FSW [35,36]. Entry points into PrEP include self-referral, HIV testing sites, family planning services, STI treatment settings and referral from community-based organizations. PrEP care occurs at primary health centers, primarily within HIV clinics and is not differentiated for key populations

For the current study, we recruited participants from three health centers in Kigali (Busanza, Remera and Gikondo), as well as from seven community KP associations of GBMSM and FSW that operate in Kigali and with whom our research group has an ongoing academic-community collaboration. The participating health centers are considered “friendly” and less stigmatizing by many GBMSM in Kigali and have fairly robust PrEP programs.

Participant recruitment

To recruit participants for the study, research staff visited health centers and KP associations to present the study to providers, solicit input on data collection instruments, and request assistance in identifying individuals who were on PrEP, who had stopped PrEP, and who had been evaluated for but never initiated PrEP. Providers at the three health centers and at the KP associations were asked to provide brief information about the study to potential participants, and refer individuals who expressed interest in participation to study staff for eligibility screening. We included participants who: 1) were HIV-negative by self-report; 2) self-identified as GBMSM or FSW; 3) were at least 18 years of age. Individuals who were unable to communicate in Kinyarwanda or unable to provide informed consent were excluded. We purposefully recruited individuals who were using PrEP at the time of the interview, had previously used PrEP but were not using it at the time of the interview, and individuals who had never used PrEP, such that the sample was approximately evenly divided between these categories. Participants received a stipend of 10,000 RWF (approximately $10) for their time. Recruitment began on June 8, 2022 and ended on July 22, 2022.

Data collection

We developed a semi-structured interview guide informed by the socio-ecological model (S1 Text). The interview guide explored individual and structural barriers to and facilitators of PrEP engagement, as well as preferences for PrEP care delivery, using open-ended questions as well as specific probes to explore areas of particular interest. All participants provided written informed consent prior to enrolling in the study and being interviewed. Interviews lasting approximately 60–90 minutes were conducted in Kinyarwanda language (the language most commonly spoken in Rwanda) by four Rwandan research staff including one psychologist (CI) and three social workers (JG, GN, FM), all with multiple years’ clinical and qualitative research experience working with GBMSM and FSW living with and at risk for HIV, and who received specific training on the interview guide developed for this study. Interviewers had no prior relationship with participants.

All interviews were conducted in a private room with the presence of study staff only, to ensure recording quality and participant privacy. Each interview was conducted by a team of two interviewers, where one led the interview and the other took field notes. Interview quality was monitored by CI, observing early interviews and providing feedback with the data collection team and JR (principal investigator) through weekly conference calls. Transcripts were reviewed and compared to field notes to ensure that they reflected all content that arose during interviews. Interview guides were iteratively refined to clarify and further explore emerging themes relevant to implementation of PrEP uptake and retention in Rwanda.

Data analysis

Audio recordings were transcribed and translated into English transcripts, which were then analyzed using both inductive and deductive thematic analysis approach to describe key barriers, facilitators and preferences. Our approach was deductive in that the investigative team developed the initial coding scheme using the socioecological model to categorize common themes, and was inductive in that we iteratively refined the codebook based on emergent themes from reading the first six transcripts. Discrepancies were discussed and resolved by consensus. Using DeDoose software (20), the final coding scheme was independently applied to all interviews by 4 coders (CI, JG, GN, FM), with each interview being coded by at least 2 investigators. The coding team regularly reviewed progress and discussed issues that arose, resolving them by consensus. These discussions also helped to establish that saturation had been reached. After all interviews were coded, excerpts were reviewed, examining themes within each code as well as between codes and using the constant comparative method to identify, refine and consolidate emergent themes. Specifically, the analytic team examined “repeating ideas” within each code to identify emergent themes. Emergent themes were entered into a matrix, looking specifically at barriers to, facilitators of and preferences for PrEP use at different levels of the SEM. Throughout the analysis phase, the team regularly met to discuss and achieve consensus on emerging themes.

Results

From June–July 2022, we interviewed 32 participants. The median age of participants was 31; 18 (56%) were GBMSM and 14 (44%) were FSW. Overall, 12 participants were using PrEP at the time of interview, 9 had previously used PrEP, and 11 had never used PrEP (Table 1). Analysis revealed four major themes: (1) social networks as key sources of PrEP information and support; (2) PrEP as protective to individuals and to the community; (3) multiple, but differing, stigmas as barriers to PrEP engagement; and (4) community access as an important strategy to improve PrEP engagement.

Table 1. Participant characteristics.

KP Category
FSW (N = 14) GBMSM (N = 18)
Age categories
 <25 years 4 (29%) 5 (28%)
 25–30 years 2 (14%) 7 (39%)
 >30 years 8 (57%) 6 (33%)
Education Level
 No school or primary school only 9 (64%) 2 (11%)
 Some secondary school 4 (29%) 11 (61%)
 University 1 (7%) 5 (28%)
PrEP use
 Current 6 (42%) 6 (33%)
 Prior 3 (21%) 6 (33%)
 Never 5 (37%) 6 (34%)
Sex at birth
 Female 14 (100%) 0 (0%)
 Male 0 (0%) 18 (100%)
Sexual Partners
 Men 14 (100%) 12 (67%)
 Men and Women 0 (0%) 6 (33%)
Number of sexual partners in past 6 months
 1–10 1 (7%) 17 (94%)
 11–20 4 (29%) 1 (6%)
 >20 9 (64%) 0 (0%)
STI diagnosis in prior 6 months 7 (50%) 2 (11%)
Exchange sex for money in prior 6 months 14 (100%) 6 (33%)
Reported challenges related to condom use during sex
 No challenges 5 (36%) 9 (50%)
 Sexual partners refuse condoms because we use PrEP 0 (0%) 1 (6%)
 Condoms feel uncomfortable 8 (57%) 3 (17%)
 Condoms reduce pleasure 1 (7%) 5 (28%)
Time since most recent HIV test
 ≤1 month 1 (7%) 7 (39%)
 2–4 months 8 (57%) 8 (44%)
 ≥5 months 4 (29%) 2 (11%)

Social networks as key sources of PrEP information and motivation

Overall, participants were familiar with PrEP, although many reported that overall knowledge about it in Rwandan society, and even among the communities of GBMSM and sex workers, was lacking.

For both GBMSM and FSW, social networks, including friends, peers, community mobilizers, and KP associations, emerged as key sources of PrEP information, mediated through the trust, acceptance and lack of stigma in these relationships. At the interpersonal level, participants described a high degree of trust in information that came from friends and peers; individuals who used PrEP felt comfortable sharing information within their communities about its benefits as well as how to access it. The potential for friends and peers to also benefit from PrEP was described as a strong motivation to share information widely, highlighting the key role of these networks as a source of counseling and information. However, many were hesitant to share information about PrEP more broadly because of the potential discrimination they might experience.

“I knew it from others because sometimes we talk as friends. So, my friends told me some who are [living with HIV] and those who are [HIV negative]; I used to think that only [people living with HIV] have ART to take but my friends told me that also [people who are HIV-negative] take PrEP due to the fact that some engage in commercial sex which can result into HIV infection. For that reason, I approached a health center for details and the medicine as well, so that I can take it.”

- 31-year-old female, currently on PrEP

“I shared it with many people. Most of the time it was to encourage them by saying, ‘It would be great if you take it.’…I disclosed it to our community members because it felt normal. I did not share it with non-members of our community.

- 32-year-old male, previously on PrEP

Although most participants felt that the information acquired through social networks was accurate, some described how incorrect (e.g., regarding cost) or negative (e.g., emphasizing side effects) information circulating in these networks discouraged some individuals from engaging in PrEP. One participant described misinformation about uncommon medication side effects:

“There exist a lot of rumors that the medicine causes acne and so on. A friend of mine told me that it has caused him facial acne… though I haven’t seen it yet - just rumors - but it’s said that it causes obesity and heart-related effects.”

- 33-year-old male, currently on PrEP

At the institutional level, health care providers, including physicians, nurses and community health workers, were felt by most participants to be trustworthy sources of information about PrEP. These sources were particularly important for participants who described difficulty accessing accurate PrEP information through more informal means or who already had an established connection to health centers. As one sex worker explained:

We went to there for general treatment, then we heard doctors who were teaching and we were curious to listen to what they were teaching about; we came to find that it was about this PrEP. Then we said, ‘Maybe this is helpful. Let’s proceed.’ We approached the nurse, she fully explained it to us, she filed us, and she started giving us the medicine. She helped us.

- 25-year-old female, currently on PrEP

However, for some participants, particularly GBMSM, stigmatizing attitudes from health care providers overshadowed the perceived and actual benefits of learning about PrEP in health care settings. While participants appreciated the information, counseling and support offered by many health workers, many wished these resources were available in less stigmatizing settings.

‘’Sometimes the health care workers are not aware of particular communities. Let me start with the LGBTI community. You find that [the health care workers] do not have enough information. When they see a man wearing a skirt, they chase the person away without knowing what he seeks and sometimes they do not let him access a service, or they skip him and receive other people due to discriminating against him.”

- 31-year-old male, never on PrEP

PrEP protecting both individuals and the community

Among participants currently or previously using PrEP, a major motivator for use was the ease of mind it provided, allowing people to feel more protected from HIV. At the individual level, participants described how they felt less anxious in terms of the number of partners they had, sexual encounters that were unexpected or with unknown partners, and not needing to negotiate condom use. For sex workers in particular, economic benefits - including taking on additional clients and engaging in higher-paying condomless sex - were seen as substantial incentives for taking PrEP. For example:

‘’The foremost factor is that it’s a protection. The second, it brings inner peace; within this job we tend to worry about the infection but even after unprotected sex you feel safe as long as you’re taking the medicine.”

- 31-year-old female, on PrEP

“Most of us sleep with different unfamiliar people and without getting tested. They give us money, and due to life circumstances, you accept. When they ask to have condomless sex, you accept it as well so that your children can eat, but sometimes you take him home and he removes the condom when you did not have an agreement. That is why I take it.”

- 24-year-old female, previously on PrEP

A number of participants reflected on the community benefits of PrEP as something that motivated PrEP use. Many described HIV as a serious problem in their communities, one that required an “all hands on deck” |approach to address. In this vein, several GBMSM described how PrEP use would not only benefit themselves, but would benefit sex partners (by indirectly protecting them from HIV), the larger GBMSM community (by reducing community HIV burden), family members (by reducing the potential shame of being associated with an individual living with HIV), and Rwandan society as a whole. GBMSM in particular were highly motivated to encourage others in their network to learn more about and use PrEP so that their entire community could benefit. Some examples include:

Generally, if someone takes [PrEP], they also protect others from being exposed but when he’s infected, they shall infect others. Therefore, taking the protection also protect others.

- 31-year-old female, currently on PrEP

If my peers took [PrEP] and can prevent themselves [from acquiring HIV], it would be beneficial to me because my peer can sleep with a seropositive individual and if he doesn’t use the medication, he would contract it and he can transmit it to me if we sleep together… it forms a cycle but if he uses the medication, it would be a solution to my health.

- 31-year-old male, never on PrEP

“The country itself benefits from PrEP too, because when the number of people living with HIV reduces, the country regains its capacity. As AIDS is a deadly disease, when the mortality cases reduce, a nation retains manpower; hence, human resources will serve their nation. It reduces disputes and trauma in some families, normally when people inform their family that they’re living with HIV, conflicts arise and the family excludes them. Yet, if they are HIV negative…it brings harmony in the family, community and country as a whole.”

- 29-year-old male, never on PrEP

Multi-level stigmas impacting PrEP use for GBMSM and sex workers

Nearly all participants described HIV-related stigma and fear of discrimination as enormous barriers to PrEP engagement. A dominant theme in interviews was that because there was limited awareness of PrEP in society, and even among some health care providers, PrEP medications were confused with antiretroviral therapy for HIV, and PrEP use would be mistakenly interpreted as having positive HIV status. These fears manifested in various ways: at the interpersonal level, participants described worrying about accidental disclosure of PrEP use if medications were discovered by others; fear of being seen by acquaintances during long waits at a health center, particularly waiting at the HIV program where PrEP is distributed, and being perceived as promiscuous if their PrEP status was inadvertently disclosed. At the structural level, there was anxiety about and even direct experience with poor treatment from healthcare providers. Because of these barriers, both GBMSM and FSW took measures to limit disclosure of PrEP use to a limited number of people, mostly sex partners, friends and their medical providers. Participants described these barriers:

“On my part, stigma is also a barrier… when the client comes and says, ‘You are seropositive, that’s the medication you are taking,’ and you respond that it is a medication that prevents contracting HIV but he doesn’t believe it and you also don’t feel good about it.

- 18 year-old female, stopped PrEP

”The challenges can be faced by those who use it. The challenges would be to access it rapidly or at a nearby place. Other challenges would be among people who live in families. It can be difficult for them to take it. For them to live with different people, they would discriminate against him, thinking that he is seropositive when he takes a tablet daily.”

- 32-year-old male, stopped PrEP

‘’Stigmatization is still existing. If someone who look like a girl, goes at a health center and meet a crowd who is waiting for ART or VCT (Voluntary HIV counselling and testing) they stare and gossip about him. Outpatients, other staff such as cleaners have no training about that only care givers do. So, every time the person goes for the service, he’s excluded due to his appearance or identity. Hence saying that stigmatization really exists!”

- 29-year-old male, never on PrEP

For GBMSM, HIV-related stigma intersected with stigma around sexual orientation and gender identity. At the structural level, GBMSM participants reported anticipated and enacted intersectional stigma at health centers, including poor treatment by health care workers. Some described how community health workers living in the same communities as patients, and even medical providers working in health centers, were insufficiently trained on issues of LGBTI health and PrEP, resulting in uncomfortable experiences and explicit discrimination. These mirrored more widespread stigma and discrimination at the societal level towards GBMSM, and made it difficult for some to initiate or continue engaging in PrEP care. As one GBMSM noted:

‘’So I don’t think that all doctors all over the country have been trained on LGBTI community; even those who were trained, some of them don’t embrace it, consequently they will abuse you. Frankly, if they do not love the community, they’ll not serve you or give you bad service in case of consultation. It discourages us and we can’t dare to come back again, thinking how bad we are treated as if we’re beggars.”

- 32-year-old male, stopped PrEP

Participants described other barriers to PrEP use, including competing demands (e.g., work, distance from health center, transportation costs) that made it difficult to attend appointments, side effects leading to discontinuation, or food insecurity that made PrEP a lower priority. For many, not initiating or discontinuing PrEP was not the result of a single factor - rather, the cumulative impact of structural, logistical and stigma-related barriers made the opportunity cost of PrEP use too high. For others, there was sufficient internal or external motivation to overcome stigma, side effects, and other barriers, and continue using PrEP.

Community access as a critical strategy to improve PrEP engagement

Given the actual and anticipated discomfort and discrimination facing participants, nearly all voiced support for making access to and engagement in PrEP less stigmatizing. Participants in particular expressed their wish to engage in PrEP care in places that were safe and trusted, increase access to information and support, and decrease their exposure to discrimination and related stigma.

Participants advocated for interventions aimed at stigma reduction, such as long-acting PrEP formulations, which would avoid inadvertent disclosure associated with taking daily pills, and changing the packaging of PrEP to clearly differentiate it from antiretrovirals prescribed for HIV. Some participants, particularly GBMSM advocated for PrEP delivery in community settings, which were considered less stigmatizing, safer, more discreet and easier to access, rather than health centers. These included KP organizations, pharmacies, and even one-on-one delivery by community health workers. One participant stated,

“[Getting PrEP at a community-based, key population association] would reduce the distance covered since it would be close plus in our organization, we understand and know each other, and harassment would not occur, like the challenge I mentioned of finding many people at the health center and as a member of the community you can be afraid to pass there but I think an organization is like home, you cannot be afraid or shy but it would be better if a nurse was available as well to educate us and examine us to know our HIV status before we get the medication.”

- 28-year-old male, currently on PrEP

Others preferred receiving PrEP care in health centers, which were better resourced and provided more structured care. FSW were more likely than MSM to highlight logistical barriers to accessing care in health centers and advocate for measures to facilitate access to these settings. While some GBMSM expressed a preference for health center-based care, many felt that additional training of staff on PrEP and in particular, caring for sexual and gender minorities, was essential to ensuring adequate services. Speaking in reference to a health center considered friendly to LGBTI persons, one participant explained,

“Health centers can be included [as places to access PrEP] but the problem is that not all of them accept LGBT community. So personally, I’d consult those places because I’m very sure that their staff had trainings…”

- 24 year-old male, never on PrEP

Discussion

In this study of Rwandan GBMSM and FSW, participants described the key role of social networks as sources of PrEP information and highlighted how peers and friends in these networks helped them overcome PrEP-related barriers and provided motivation to engage in care. Our findings suggest that approaches directed at strengthening key population communities and reducing stigma related to HIV and sexual and gender identity could facilitate improved, sustained engagement in PrEP.

We found that for both GBMSM and FSW, community is a central element of PrEP engagement. Key sources of information about PrEP included formal community structures (e.g., associations, peer navigators) as well as less formal, interpersonal friendships and relationships. Participants described a high degree of trust in these sources of information and a corresponding high degree of comfort in accessing them. These findings are similar to research from other SSA settings describing high acceptability of in-person and virtual peer-led communication about PrEP for KPs [37,38], indicating that such approaches can be empowering [39] and even improve engagement in care [40]. Nonetheless, participants in this study described how erroneous or demotivating information can be amplified by community voices in ways that serve as barriers to PrEP. Countering such misinformation through general and targeted dissemination campaigns - as suggested by participants in this study and others [37–38] - could help ensure that these trusted sources provide high-quality information.

Participants reported very high levels of interpersonal and institutional stigma and discrimination related to being misidentified as living with HIV and the potential disclosure of their membership in a key population. Both GBMSM and FSW described HIV-related stigma in their communities (e.g., worry that people would see their medication and think they were using ART) as well as health centers (e.g., being considered promiscuous by health care workers), consistent with findings across SSA [41,42]. Making access to PrEP easier, more discrete, and less fraught - through long-acting injectable formulations [43], low-barrier, community-based access points, and training of providers to provide more welcoming care - was preferred by many participants. For GBMSM, HIV-related stigma was compounded by stigma related to sexual orientation and gender identity, which was felt to be pervasive in society including in many health centers, consistent with national survey data from Rwanda [31]. Because of this, many expressed a desire for PrEP delivery in LGBTI community organizations, similar to preferences identified by GBMSM in other SSA settings [38]. Notably, not all participants felt that community-based PrEP delivery options were ideal, with some preferring more formal and better resourced health settings. Recent data from the SEARCH trial in Uganda and Kenya indicate that providing individuals with choices (e.g., service location) can increase PrEP coverage [44]. While that study did not report on sexual orientation and likely included few GBMSM or FSW, our data suggest that offering options for PrEP care may be a promising strategy.

Most studies of KPs in SSA to date have examined the individual benefits of, facilitators of and barriers to PrEP, yet few have assessed the interpersonal, community aspects of prevention. We observed a high degree of community-focused PrEP motivation among both GBMSM and FSW participants, who identified HIV as a serious problem in their social networks and described how PrEP engagement could benefit sex partners, family members, and peers. These findings echo the concepts of collective antiretroviral protection and prevention solidarity, recently described by Brisson, et al [45]. Much like the idea of herd immunity - where unvaccinated individuals in a population benefit from the vaccination of others - collective protection suggests that when a substantial portion of a community remains HIV-negative (or, if living with HIV, virally suppressed), all members of the community have a reduced HIV risk. Although participants in this study did not explicitly describe the concept of collective antiretroviral protection, our results suggest that some GBMSM and FSW in Rwanda are actively considering how their individual PrEP-related decisions can benefit others around them. Rwandan society has been considered one with a high degree of social cohesion [46], and it is possible that prevention solidarity might have less potential in other settings. Nonetheless, collective HIV prevention has been described among heterosexual, serodifferent couples in Uganda and Kenya, although interpersonal dynamics may differ substantially in these relationships compared to those in broader social networks of GBMSM and FSW [47,48]. To our knowledge, prevention solidarity has not been examined among GBMSM or FSW in SSA. Understanding how to best implement collective antiretroviral protection among GBMSM and FSW in SSA could be a key step to improving and maintaining PrEP engagement.

While analysis revealed many common themes among GBMSM and FSW, we found important differences as well. For GBMSM, anticipated and experienced sexual and gender stigma in society as well as in health centers led to the social network emerging as the single most important source of information, motivation and support related to PrEP engagement. These findings are consistent with prior research we conducted highlighting the close-knit nature of these networks [23], and support recent PEPFAR recommendations to strengthen LGBTI associations to ensure dissemination of accurate PrEP information and facilitate peer linkage to PrEP [30]. FSW, in contrast, described more informal social networks and were more comfortable accessing care in health centers. Many FSW also emphasized economic motivations for PrEP use and highlighted logistical barriers. Together, these findings suggest that efforts to disseminate PrEP information and motivate engagement among GBMSM and FSW should not follow a uniform approach, and to the degree possible should be tailored to the needs of each community, aligned with calls for differentiated approaches to HIV prevention [49].

This study has several limitations. We used a single interview guide for GBMSM and FSW given the many common issues around PrEP access impacting both groups; nonetheless this may have limited our ability to fully explore existing differences between them. We did not recruit persons who had stopped and then restarted PrEP, and thus are not able to assess how their experiences may differ from persons never, previously or continuing on PrEP. Some interviews occurred in health care settings, and it is possible that participants may have felt reluctant to fully describe their perspectives on health care because of social desirability bias. Willingness to participate in research may reflect an overall lower degree of stigma, and we therefore may not have captured the perspectives of KP who are too stigmatized to enroll in a research study.

In conclusion, we found that for GBMSM and FSW in Rwanda, despite high levels of PrEP awareness in their communities, PrEP engagement remains challenging because of the potential to be misidentified as having HIV and because of stigma related to membership in a key population group. Nonetheless, participants highlighted the strength and support they experienced from peers and colleagues in their social networks, and described a strong motivation to use PrEP as a way to protect both themselves and their communities from HIV. Our findings suggest that leveraging community resources for disseminating information about HIV prevention and delivering PrEP could contribute to successful implementation of PrEP for GBMSM and FSW in Rwanda and other settings in SSA.

Supporting information

S1 Text. In-depth interview guide for study participants.

(PDF)

pgph.0004538.s001.pdf (78.8KB, pdf)
S2 Text. Questionnaire on inclusivity in global research.

(DOCX)

pgph.0004538.s002.docx (68.8KB, docx)

Data Availability

Full transcripts are not publicly available as they contain sensitive information, which, though de-identified, include personal narratives that could result in identification of individuals, and because permission for public dissemination of raw data was not solicited from participants at the time of informed consent, nor from the Rwanda National Ethics Committee. De-identified data that support the findings of this study may be made available for researchers who meet the criteria for access to confidential data upon reasonable request. For data inquiries, please contact Ms. Valentine Ingabire, secretary of the Rwanda National Ethics Committee, at info@rnecrwanda.org.

Funding Statement

The authors did not receive specific funding for this study. However, the work was supported through program grants from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute of Mental Health, and the National Institute on Drug Abuse, as part of Central Africa IeDEA (U01 AI096299); and by the Einstein-Rockefeller-CUNY Center for AIDS Research (P30-AI124414), which is supported by the following NIH Co-Funding and Participating Institutes and Centers: NIAID, NCI, NICHD, NHBL, NIDA, NIMH, NIA, FIC, and OAR. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.The Path That Ends AIDS: UNAIDS Global AIDS Update 2023. Geneva: Joint United Nations Programme On HIV/AIDS; 2023. Licence: CC BY-NC-SA 3.0 IGO. [Google Scholar]
  • 2.Barr D, Garnett P, Mayer K, Morrison M. Key populations are the future of the African HIV/AIDS pandemic. J Int AIDS Soc. 2021;24 Suppl 3:e25750. doi: 10.1002/jia2.25750 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Garnett GP. Reductions in HIV incidence are likely to increase the importance of key population programmes for HIV control in sub-Saharan Africa. J Int AIDS Soc. 2021;24 Suppl 3:e25727. doi: 10.1002/jia2.25727 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.New HIV infections among key populations, proportions in 2010 and 2022. Geneva: Joint United Nations Programme on HIV/AIDS; 2024. Licence: CC BY-NC-SA 3.0 IGO. [Google Scholar]
  • 5.Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. doi: 10.1056/NEJMoa1011205 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Baeten J, Donnell D, Ndase P, Mugo N, Campbell J, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Fonner V, Dalglish S, Kennedy C, Baggaley R, O’Reilly K, Koechlin F, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;30:1973–83. doi: 10.1097/QAD.0000000000001145 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Landovitz R, Donnell D, Clement M, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385:595–608. doi: 10.1056/NEJMoa2101016 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.World Health Organization, Department of HIV/AIDS. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection 2016: Recommendations for a public health approach. Geneva, Switzerland: World Health Organization, 2016. [Google Scholar]
  • 10.Global State of PrEP. [cited March 6, 2022]. Available from: https://www.who.int/groups/global-prep-network/global-state-of-prep [Google Scholar]
  • 11.Schaefer R, Schmidt H, Ravasi G, Mozalevskis A, Rewari B, Lule F, et al. Adoption of guidelines on and use of oral pre-exposure prophylaxis: a global summary and forecasting study. Lancet HIV. 2021;8:e502–10. doi: 10.1016/S2352-3018(21)00127-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Isano S, Yohannes T, Igihozo G, Ndatinya G, Wong R. A qualitative study to explore the healthcare-seeking experiences of men who have sex with men (MSM) and transgender women (TGW) in Rwanda. BMC Health Serv Res. 2023;23(1):291. doi: 10.1186/s12913-023-09286-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yi S, Tuot S, Mwai G, Ngin C, Chhim K, Pal K, et al. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in low- and middle-income countries: a systematic review and meta-analysis. J Int AIDS Soc 2017;20:21580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Parmley L, Harris T, Chingombe I, Mpaingure M, Mugurungi O, Rogers J, et al. Engagement in the pre-exposure prophylaxis (PrEP) cascade among a respondent-driven sample of sexually active men who have sex with men and transgender women during early PrEP implementation in Zimbabwe. J Int AIDS Soc. 2022;25:e25873. doi: 10.1002/jia2.25873 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ogunbajo A, Tsai A, Kanki P, Mayer K. Acceptability of and preferences for long-acting injectable HIV PrEP and Other PrEP modalities among sexual minority men in Nigeria, Africa. AIDS Behav 2022. DOI:10.1007/s10461-022-03575-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Sun Z, Gu Q, Dai Y, Zou H, Agins B, Chen Q, et al. Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta-analysis of global data. J Int AIDS Soc. 2022;25:e25883. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Munyaneza A, Adedimeji A, Kim H-Y, Shi Q, Hoover DR, Ross J, et al. Awareness and willingness to use HIV pre-exposure prophylaxis among men who have sex with men in rwanda: a cross-sectional descriptive survey. J Assoc Nurses AIDS Care. 2021;32(6):693–700. doi: 10.1097/JNC.0000000000000228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Were D, Musau A, Mutegi J, Ongwen P, Manguro G, Kamau M, et al. Using a HIV prevention cascade for identifying missed opportunities in PrEP delivery in Kenya: results from a programmatic surveillance study. J Int AIDS Soc. 2020;23 Suppl 3:e25537. doi: 10.1002/jia2.25537 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Martin V, Tesha N, Sunguya B. Uptake of oral HIV pre-exposure prophylaxis (PrEP) and associated factors among female sex workers in Tanga, Tanzania. Viruses. 2023;15:2125. doi: 10.3390/v15102125 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Guure C, Afagbedzi S, Torpey K. Willingness to take and ever use of pre-exposure prophylaxis among female sex workers in Ghana. Medicine. 2022;101:e28798. doi: 10.1097/MD.0000000000028798 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Busza J, Phillips A, Mushati P, Chiyaka T, Magutshwa S, Musemburi S, et al. Understanding early uptake of PrEP by female sex workers in Zimbabwe. AIDS Care. 2021;33:729–35. doi: 10.1080/09540121.2020.1832192 [DOI] [PubMed] [Google Scholar]
  • 22.Shea J, Bula A, Dunda W, Hosseinipour M, Golin C, Hoffman I, et al. “The Drug Will Help Protect My Tomorrow”: perceptions of integrating prep into hiv prevention behaviors among female sex workers in Lilongwe, Malawi. AIDS Educ Prev. 2019;31:421–32. doi: 10.1521/aeap.2019.31.5.421 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Adedimeji A, Sinayobye J, Asiimwe-Kateera B, Chaudhry J, Buzinge L, Gitembagara A, et al. Social contexts as mediator of risk behaviors in Rwandan men who have sex with men (MSM): implications for HIV and STI transmission. PLoS One. 2019;14:e0211099. doi: 10.1371/journal.pone.0211099 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Isano S, Yohannes T, Igihozo G, Ndatinya G, Wong R. A qualitative study to explore the healthcare-seeking experiences of men who have sex with men (MSM) and transgender women (TGW) in Rwanda. BMC Health Serv Res. 2023;23:291. doi: 10.1186/s12913-023-09286-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Stannah J, Dale E, Elmes J, Staunton R, Beyrer C, Mitchell K, et al. HIV testing and engagement with the HIV treatment cascade among men who have sex with men in Africa: a systematic review and meta-analysis. Lancet HIV. 2019;6:e769–87. doi: 10.1016/S2352-3018(19)30239-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ministry of Finance and Economic Planning, National Institute of Statistics of Rwanda. Fifth Rwanda Population and Housing Census. Kigali, Rwanda. 2022. [cited 2024 Jun 21]. Available from: https://www.statistics.gov.rw/datasource/fifth-population-and-housing-census-2022. [Google Scholar]
  • 27.Musengimana G, Tuyishime E, Remera E, Dong M, Sebuhoro D, Mulindabigwi A, et al. Female sex workers population size estimation in Rwanda using a three-source capture-recapture method. Epidemiol Infect. 2021;149:e84. doi: 10.1017/S0950268821000595 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Tuyishime E, Kayitesi C, Musengimana G, Malamba S, Moges H, Kankindi I, et al. Population size estimation of men who have sex with men in Rwanda: three-source capture-recapture method. JMIR Public Health Surveill. 2023;9:e43114. doi: 10.2196/43114 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Rwanda Biomedical Center (RBC). Rwanda Population-Based HIV Impact Assessment (RPHIA) 2018-2019: Final Report. Kigali: RBC; 2020. [cited 2023 Sep 9]. https://phia.icap.columbia.edu/rwanda-final-report/. [Google Scholar]
  • 30.Dutcher R. 2022 Country operational plan guidance. United States Department of State. 2022. [cited 2022 Jul 13]. https://www.state.gov/2022-country-operational-plan-guidance/. [Google Scholar]
  • 31.Examination of LGBT People’s Lived Experiences and Public Perceptions of Sexual and Gender Minorities in Rwanda. 2022. Nairobi, Kenya: APHRC and HDI. [Google Scholar]
  • 32.“PEPFAR. Rwanda Country Operational Plan (COP/ROP), Strategic Direction Summary. U.S. Department of State, 2018. [cited 2025 Mar 3]. Available from: https://www.state.gov/wp-content/uploads/2019/08/rwanda-2.pdf. [Google Scholar]
  • 33.Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349–57. doi: 10.1093/intqhc/mzm042 [DOI] [PubMed] [Google Scholar]
  • 34.Mubezi S, Rwibasira GN, Uwineza J, Kayisinga J, Wandera M, Malamba S, et al. Factors associated with retention on pre-exposure prophylaxis among female sex workers in Kigali, Rwanda. PLOS Glob Public Health. 2023;3:e0002524. doi: 10.1371/journal.pgph.0002524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Rugira E, Biracyaza E, Umubyeyi A. Uptake and persistence on HIV pre-exposure prophylaxis among female sex workers and men having sex with men in Kigali, Rwanda: a retrospective cross-sectional study design. Patient Prefer Adherence. 2023;17:2353–64. doi: 10.2147/PPA.S427021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Munyaneza A, Bhutada K, Shi Q, Zotova N, Nsereko E, Muhoza B, et al. High retention among key populations initiated on HIV pre-exposure prophylaxis in Kigali City, Rwanda. J Int AIDS Soc. 2024;27(11):e26392. doi: 10.1002/jia2.26392 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Reyniers T, Babo SAY, Ouedraogo M, Kanta I, Agbegnigan L, Rojas D, et al. Strategies to improve PrEP uptake among West African men who have sex with men: a multi-country qualitative study. Front Public Health. 2023;11:1165327. doi: 10.3389/fpubh.2023.1165327 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Perez-Urbano I, Dilraj A, Pitsi A, Hlongwane N, Abdelatif N, et al. Strategies to Close the PrEP Uptake Gap Among Transgender People and Men Who Have Sex with Men in Tshwane, South Africa: Perspectives from the Community. AIDS Behav. 2024. doi: 10.1007/s10461-024-04300-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Goymann H, Mavuso M, McMahon SA, Hettema A, Hughey AB, Matse S, et al. “We Should Not Be Quiet but We Should Talk”: qualitative accounts of community-based communication of HIV pre-exposure prophylaxis. Qual Health Res. 2023;33:842–56. doi: 10.1177/10497323231181207 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Eubanks A, Coulibaly B, Keita B, Anoma C, Dah T, Mensah E, et al. Loss to follow-up from HIV pre-exposure prophylaxis care in men who have sex with men in West Africa. Viruses. 2022;14:2380. doi: 10.3390/v14112380 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Sundararajan R, Wyatt M, Muwonge T, Pisarski E, Mujugira A, Haberer J, et al. Understanding PrEP acceptability among priority populations: results from a qualitative study of potential users in Central Uganda. AIDS Behav. 2022;26:2676–85. doi: 10.1007/s10461-022-03606-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Stoebenau K, Muchanga G, Ahmad S, Bwalya C, Mwale M, Toussaint S, et al. Barriers and facilitators to uptake and persistence on PrEP among key populations in Southern Province, Zambia: a thematic analysis. 2024. doi: 10.21203/rs.3.rs-3788854/v1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Reyniers T, Fiorentino M, Babo S, Ouedraogo M, Kanta I, Agbegnigan L, et al. The perceived added value of bimonthly injectable pre-exposure prophylaxis according to West African men who have sex with men: a focus group study. AIDS Patient Care STDS. 2023;37:480–8. [DOI] [PubMed] [Google Scholar]
  • 44.Kakande E, Ayieko J, Sunday H, Biira E, Nyabuti M, Agengo G, et al. A community-based dynamic choice model for HIV prevention improves PrEP and PEP coverage in rural Uganda and Kenya: a cluster randomized trial. J Int AIDS Soc. 2023;26:e26195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Brisson J, Grace D, Perez-Brumer A. Collective antiretroviral protection: new dimensions of community HIV prevention practices at the intersection of U=U and PrEP. Lancet HIV. 2024;e341–4. doi: 10.1016/S2352-3018(24)00034-1 [DOI] [PubMed] [Google Scholar]
  • 46.Hilditch S. Unity and reconciliation in Rwanda: A look at policy implications vis-à-vis social cohesion. International Alert. 2018. [cited 2024 May 24]. Available from: https://www.international-alert.org/publications/unity-and-reconciliation-rwanda/ [Google Scholar]
  • 47.McMahon JM, Simmons J, Braksmajer A, LeBlanc N. HIV-serodifferent couples’ perspectives and practices regarding HIV prevention strategies: a mixed methods study. PLOS Glob Public Health. 2022;2:e0000620. doi: 10.1371/journal.pgph.0000620 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Musoke P, Darbes L, Hatcher AM, Helova A, Kwena Z, Owino G, et al. Couple efficacy and communal coping for HIV prevention among kenyan pregnant couples. AIDS Behav. 2022;26:2135–47. doi: 10.1007/s10461-021-03559-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Macdonald V, Verster A, Baggaley R. A call for differentiated approaches to delivering HIV services to key populations. J Int AIDS Soc. 2017;20:21658. [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004538.r002

Decision Letter 0

Marie A Brault

31 Jan 2025

PGPH-D-24-02716

PrEP in the key population community: a qualitative study of perspectives on pre-exposure prophylaxis by men who have sex with men and female sex workers in Kigali, Rwanda

PLOS Global Public Health

Dear Dr. Ross,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

Editor comments:

  • The reviewers and I found the manuscript to be well-written and offer important insights into the experiences of key populations concerning PrEP in Rwanda. However, there are a few areas where clarifications would strengthen the clarity and impact of the manuscript.

  • I agree with the reviewers' recommendations to ensure that person-centered language is used to refer to key populations throughout. Please also note and address the questions concerning qualitative data collection and participant recruitment, and consider whether these aspects might need to be discussed as study limitations.

  • In addition to the reviewers' comments, I would encourage the authors to expand the background and introduction to provide more information on the context of key populations in Rwanda and the policy/legal environment. In the discussion, the paper references that the study city has a "relatively tolerant policy climate with respect to sexual health", but it isn't clear what that means or how that might play a role in interpreting findings, beyond being cited as a limitation. Additionally, given that the goal of qualitative studies is not generalizability, but instead an in-depth understanding of experiences and context, it isn't clear to me how this aspect would necessarily constitute a limitation.

==============================

Please submit your revised manuscript by Mar 02 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Marie A. Brault, PhD

Academic Editor

PLOS Global Public Health

Journal Requirements:

1. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met. Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/globalpublichealth/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

2. Please amend your detailed Financial Disclosure statement. This is published with the article. It must therefore be completed in full sentences and contain the exact wording you wish to be published.

**Please only choose the relevant sentences from below**

i. Please clarify all sources of funding (financial or material support) for your study. List the grants (with grant number) or organizations (with url) that supported your study, including funding received from your institution. 

ii. State the initials, alongside each funding source, of each author to receive each grant.

iii. State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

iv. If any authors received a salary from any of your funders, please state which authors and which funders.

3. We have amended your Competing Interest statement to comply with journal style. We kindly ask that you double check the statement and let us know if anything is incorrect. 

4. In the online submission form, you indicated that "The datasets analyzed during the current study are available from the corresponding author on reasonable request.". 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 

1. In a public repository, 

2. Within the manuscript itself, or 

3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons by return email and your exemption request will be escalated to the editor for approval. Your exemption request will be handled independently and will not hold up the peer review process, but will need to be resolved should your manuscript be accepted for publication. One of the Editorial team will then be in touch if there are any issues.

5. We have noticed that you have uploaded Supporting Information files, but you have not included a list of legends. Please add a full list of legends for your Supporting Information files after the references list. 

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria ? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: N/A

Reviewer #3: Yes

Reviewer #4: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

Reviewer #4: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This well-executed and written study describes the qualitative barriers and facilitators of PrEP use among men who have sex with men and female sex workers in Kigali. It provides useful comparisons of different motivators and barriers, and includes an interesting discussion of social cohesion and importance of collective benefits of PrEP in this setting. It is a valuable addition to the literature and only minor edits are suggested.

Pg. 3, line 87: instead of “high-risk groups”, prioritise using people-centred language that doesn’t define people solely by their risk. e.g. “groups with higher risk of acquiring HIV”.

Pg. 3, line 88: Is the number receiving PrEP medication based on having received it at least once? Are there any data on PrEP continuation that could also be cited here? Not knowing the population size estimates of MSM and FSW in Rwanda/Kigali, is there any estimate of the proportion of these groups who are on or who have started PrEP?

Pg. 8, line 252: Is colleague the correct translation here, referring to coworker ?

Pg. 9, line 291: Based on some of the included quotes, also implies stigma experienced around gender identity and expression.

Reviewer #2: This well-written manuscript presents a qualitative analysis of cisgender female sex workers and gay, bisexual, and other men who have sex with men in Kigali, Rwanda. While several findings have been previously published, and it would have been preferable to avoid the comingling of qualitative data from these two distinct populations—given that existing research highlights differences in their health experiences—the paper is noteworthy for exploring “collective antiretroviral protection” as a sexual health strategy. A strength of the study is that participants were recruited from facility and community settings and included current, former, and never PrEP users. However, the PrEP perspectives of never-users are well described in the literature; thus, including PrEP re-initiators would have been more interesting, given how users cycle on and off PrEP. Given that intersecting stigmas are recognized as a critical and complex barrier to the uptake of evidence-based HIV prevention interventions, it would have been beneficial to organize the Results (third theme) and Discussion in line with the Socio-Ecological Model, which the authors indicate they referenced in designing the interview guide. I have a few comments which the authors might find helpful.

1) Abstract and Introduction—The authors state that “limited data exist describing experiences and preferences of GBMSM and FSW with respect to accessing and using PrEP” as a rationale for their study. However, a PubMed search (MSM AND PrEP AND Qualitative AND Africa) revealed 23 studies, suggesting their PrEP experiences have been amply described in the literature.

2) Introduction and Methods: Please clarify that this is a study of oral PrEP, given the availability of PrEP rings and injections as alternative formulations.

3) Methods: Participants were recruited from June-July 2022 but interviewed from November-December 2022. What accounts for this five-month gap? Did all who indicated interest in the study eventually participate in interviews, or did some drop off or could not be reached five months later? Were all participants who were approached interviewed, or did some decline? Reasons for refusal should be described in the Results.

4) Methods: Line 111 refers to an interview guide. Were separate interview guides used for FSW and GBMSM? If not, this should be acknowledged as a limitation as these are distinct sub-populations.

5) Results, Table 1. Six GBMSM reported sex with both women and men, but marital status was not reported. Were they married to women to fulfill cultural and religious norms to have children and to avoid discrimination, as often happens in this setting?

6) Results, lines 163-170: This text is unrelated to the social networks theme and can be moved to after the sentence ending on line 159.

7) Results–Quantification of qualitative research. It is tempting to describe qualitative data using quantitative terms, e.g., “a high level of knowledge about PrEP” (how was this measured?), “a substantial number of participants,” or “tremendous amount of anticipated and enacted stigma” (how was this measured?) but this is best avoided.

8) Discussion: The authors state in the Methods that the socioecological model was used to explore individual and structural PrEP barriers and facilitators. However, this is not evident in the Results (lines 352-367), which do not appear to discuss the findings through the lens of individual, interpersonal, intersectional, or structural stigma.

9) Discussion: Whereas stigma and discrimination in healthcare settings were described in the Results, there is no mention of gender sensitivity training for providers as a possible solution. Additionally, the paper does not mention sex work stigma (sex work is criminalized in Rwanda), particularly for GBMSM who sold sex, as per Table 1.

10) Discussion: Generalizability – avoid the temptation to generalize findings from FSW and GBMSM in one urban setting by saying your “data suggest that offering options for PrEP care would be well received by key populations in SSA.”

11) Language: The NIAID HIV Language Guide recommends not using the term MSM because it is stigmatizing. Gay, bisexual, and other men who have sex with men (GBMSM) is preferred. Moreover, Table 1 indicates that some of these men were bisexual, which speaks to the limitations of describing this population as MSM.

Other comments

12) Line 59: Clarify that the population under study is cisgender FSW and GBMSM. Currently, the reader only finds this out after seeing sex at birth data in Table 1.

13) Lines 87-88: FSW and MSM were defined in the Introduction and do not need to be written in full in the Methods.

14) Lines 148-149: Please provide a citation for the COREQ guidelines.

15) Line 382: The preferred term is “serodifferent” not serodiscordant.

Reviewer #3: A well-written manuscript with a good review of literature.

Few comments:

- In qualitative research, the interviewer is the instrument. You have mentioned that three researchers were trained (?) on qualitiative research. Those interviewers need to be well versed with exploration and proping of issues and potential themes.

- I have concerns about the emerging themes. Who decided to stop at this number of participants? Generally, we are looking for saturation in emerged themes before we decide to stop further recruitment. I cannot see any discussion about this.

- Would be good if you present information about recruitment- i.e. how many approached and how many refused to participate. This will give an additional idea about enrolled individuals- as you highlighted mught be very motivated. You also need to present information about recruitment of individuals from each recruitment centre, the three medical centre and 7 community centres.

Reviewer #4: Thank you for the opportunity to review this draft manuscript.

Overall, the paper is clear and well-written and was enjoyable to read.

Background

-Section that states that current care models are not optimized for KPs can be expanded to be more descriptive of what current care models there are and why they are not working well, or describe that they are tailored towards other risk groups. The evidence described on factors does not explicitly speak to this. But this implies that PrEP services are not differentiated to the population, for example primarily being clinic/health facility based. But some description of this and references would be helpful.

-Suggest including a citation for the government of Rwanda initiation of PrEP for KPs (first line of 3rd paragraph)

-For context for the reader, in the background or methods, could indicate if same-sex sexual activity is considered legal in Rwanda, as well as if sex work is legal or criminalized in the country. This may be influential in terms of how individuals access care/stigma felt, etc. and this information would be helpful for the reader.

Methods

-Is there any population estimate for FSW and MSM – in Rwanda overall, or in Kigali? This will be helpful, as list the number of individuals on PrEP as of June 2023.

-FSW and MSM are spelled out in paragraph 2 of the Methods – as acronym has already been used, can use consistently throughout paper

-In the methods, it is indicated that individuals were purposefully recruited to include those that were using PrEP, had previously used PrEP, and those that had never used PrEP. Is there a eligibility screening tool that was used that can be provided as part of the supplementary materials? The in-depth interview guide provided asks questions including ‘Have you ever heard of PrEP?’, but to be recruited, it seems like this question would already have been asked/known? Same with have you ever used PrEP question.

-Please review the interview guide provided. In one place it indicates in Section II, Question 2, have you ever used PrEP, if no, ask 2a, and skip to Section II. I think this means skip to Section III. Please review and revise as needed.

Results

T-he time between recruitment and interviews was long (several months). Were any individuals recruited lost to follow-up because of this delay between recruitment and interview?

-Spell out LGBTI at first use

-There are a number of yes/no questions in the interview guide – have you considered adding these to the results?

-Additional quotations from participants in the stigma section of the results could be beneficial. In particular, in this section there is not a quote from a FSW.

-Additional quotes in the community access results section would be beneficial to the paper.

-Overall, the FSW point of view in the results seems limited. Were there any differences by KP group in terms of how delivery of PrEP is preferred (i.e., in the community or at a health center, delivery at home by a community health care workers…?). I see now that this is mentioned in a paragraph in the discussion – emphasizing the importance of differentiated care, however, it would be beneficial to include these findings in the results, as that is not clear currently.

Discussion

-Some of the probes used in the interview guide seem leading – i.e., biggest challenges accessing PrEP. Did the probes influence the participants’ responses in any way? Is this a potential limitation to add?

-As the study made sure to include individuals who were currently on PrEP, had stopped PrEP, had never started PrEP, were the data analyzed by these disaggregations in any way?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #1: No

Reviewer #2: No

Reviewer #3: Yes:  Haider Al-Darraji

Reviewer #4: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Review-PrEP in the key population community.pdf

pgph.0004538.s003.pdf (32.7KB, pdf)
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0004538.r004

Decision Letter 1

Marie A Brault

3 Apr 2025

PrEP in the key population community: a qualitative study of perspectives on pre-exposure prophylaxis by gay, bisexual and other men who have sex with men and female sex workers in Kigali, Rwanda

PGPH-D-24-02716R1

Dear Dr. Ross,

We are pleased to inform you that your manuscript 'PrEP in the key population community: a qualitative study of perspectives on pre-exposure prophylaxis by gay, bisexual and other men who have sex with men and female sex workers in Kigali, Rwanda' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Marie A. Brault, PhD

Academic Editor

PLOS Global Public Health

***********************************************************

Reviewer Comments (if any, and for reference):

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

Reviewer #4: All comments have been addressed

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria ? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #2: Yes

Reviewer #4: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: N/A

Reviewer #4: N/A

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No

Reviewer #4: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: Yes

Reviewer #4: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

Reviewer #4: Thank you for responding to all reviewer comments and incorporating feedback into the manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean? ). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy .

Reviewer #2: No

Reviewer #4: No

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. In-depth interview guide for study participants.

    (PDF)

    pgph.0004538.s001.pdf (78.8KB, pdf)
    S2 Text. Questionnaire on inclusivity in global research.

    (DOCX)

    pgph.0004538.s002.docx (68.8KB, docx)
    Attachment

    Submitted filename: Review-PrEP in the key population community.pdf

    pgph.0004538.s003.pdf (32.7KB, pdf)
    Attachment

    Submitted filename: response_to_reviewers.docx

    pgph.0004538.s005.docx (138.7KB, docx)

    Data Availability Statement

    Full transcripts are not publicly available as they contain sensitive information, which, though de-identified, include personal narratives that could result in identification of individuals, and because permission for public dissemination of raw data was not solicited from participants at the time of informed consent, nor from the Rwanda National Ethics Committee. De-identified data that support the findings of this study may be made available for researchers who meet the criteria for access to confidential data upon reasonable request. For data inquiries, please contact Ms. Valentine Ingabire, secretary of the Rwanda National Ethics Committee, at info@rnecrwanda.org.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES